Renalytix Plc (RNLX)の価格はいくらですか

Renalytix Plc (RNLX)の価格は$0.1502です

Renalytix Plc (RNLX)の時価総額は何ですか

Renalytix Plc (RNLX)の時価総額は$6.43Mです

Renalytix Plc（RNLX）株式分割

Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.

年	株式分割	分割比率	累積分割比率
提供された日付のデータは十分ではありません。

年

株式分割

分割比率

累積分割比率

提供された日付のデータは十分ではありません。

企業	累積分割比率	国
GE HealthCare Technologies Inc. GEHC.US	-	US
Pro Medicus Limited PME.AX	-	AU
BrightSpring Health Services, Inc. Common Stock BTSG.US	-	US
Tempus AI, Inc. TEM.US	-	US
Signify Health, Inc. SGFY.US	-	US

企業

株式分割の回数

累積分割比率

国